CA 19-9 in pancreatic cancer

Surgical Oncology Clinics of North America

Volumn 7, Issue 1, 1998, Pages 93-101

  Ritts, R E ^a   Pitt, H A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR ANTIGEN;

CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; PANCREAS CANCER; PANCREAS RESECTION; PATIENT MONITORING; PATIENT SELECTION; PROGNOSIS; REFERENCE VALUE; REVIEW;

EID: 0031886205     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1055-3207(18)30286-2     Document Type: Review

References (40)

1. Aziz D. Clinical use of tumor markers based on outcome analysis Laboratory Medicine 27 1996 817 821
2. Bluemke D. Abrams R. Yeo C. Recurrent pancreatic adenocarcinoma: Spiral CT evaluation following the Whipple procedure Radiographics 17 1997 303 313
3. Carlucci M. Zerbi A. Parolini D. CT-guided pancreatic percutaneous fine-needle biopsy in differential diagnosis between pancreatic cancer and chronic pancreatitis HPB Surg 1 1989 309 314
4. DelMaschio A. Vanzulli A. Sironi S. Pancreatic cancer versus chronic pancreatitis: Diagnosis with CA 19-9 assessment, US, CT and CT-guided fine-needle biopsy Radiology 178 1991 95 99
5. Fabris C. Basso D. Piccoli A. Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer J Med 22 1991 145 156
6. Forsmark C. Lambiase L. Vogel S. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA 19-9 Pancreas 9 1994 731 734
7. Foutch P. A diagnostic approach to pancreatic cancer Dig Dis 12 1994 129 138
8. Gattani A. Mandeli J. Bruckner H. Tumor markers in patients with pancreatic carcinoma Cancer 78 1996 57 62
9. Greiner J. Guadagni F. Goldstein D. Evidence for the elevation of serum carci- noembryonic antigen (CEA) and tumor-associated glycoprotein-72 (TAG-72) in patients administered interferon Cancer Res 51 1991 4155 4163
10. Haglund C. Kuusela P. Roberts P. Tumor markers in pancreatic cancer Ann Chir Gynaecol 78 1989 41 53
11. Ishii H. Okada S. Sato T. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer Hepatogastroenterology 44 1997 279 283
12. Itkowitz S. Kim Y. New carbohydrate tumor markers Gastroenterology 90 1986 491 494
13. Koelbl H. Schieder K. Neunteufel W. A comparative study of mucin-like carcinoma- associated antigen (MCA), CA 125, CA 19-9, and CEA in patients with ovarian cancer Neoplasma 36 1989 473 478
14. Kolb G. Safi F. Berger H. The diagnostic value of CA 19-9 in patients with pancreatic cancer and non specific GI-symptoms Programs and Abstracts of the Annual Meeting of the American Society for Clinical Oncology 1996 A34
15. Koprowski H. Herlyn M. Steplewski Z. Specific antigen in serum of patients with colon carcinoma Science 212 1981 53 55
16. Koprowski H. Steplewski Z. Mitchell K. Colorectal carcinoma antigens detected by hybridoma antibodies Somatic Cell Genetics 5 1979 957 972
17. Lundin J. Roberts P. Kuusela P. Prognostic significance of serum CA 242 in pancreatic cancer: A comparison with CA 19-9 Anticancer Res 15 5B 1995 2181 2186
18. Magnani J. Nilsson B. Brockhaus M. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fu- copenteose II J Biol Chem 257 1982 14365 14369
19. Malesci A. Montorsi M. Mariani A. Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: A prospective study Pancreas 7 1992 497 502
20. Molina L. Diez M. Cava M. Tumor markers in pancreatic cancer: A comparative clinical study between CEA, CA 19-9, and CA 50 Int J Biol Markers 5 1990 127 132
21. Niederau C. Grendell H. Diagnosis of pancreatic carcinoma: Imaging techniques and tumor markers Pancreas 7 1992 66 86
22. Ng W. Tong K. Tam T. Clinical values of CA 19-9, CA 125 and CEA in malignant obstructive jaundice Chung-Hua I Hsueh Tsa Chih (Taipei) 55 1995 438 446
23. O’Connell M. Ritts R. Moertel C. Recombinant gamma-interferon lacks activity against metastatic colorectal cancer but increases serum levels of CA 19-9 Cancer 63 1989 1998 2004
24. Pasquali C. Sperti C. D’Andrea A. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma: Comparison with CA 19-9 Int J Pancreatol 15 1994 171 177
25. Pasquali C. Sperti C. D’Andrea A. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma Ital J Gastroenterol 26 1994 169 173
26. Plebani M. Basso D. Panozzo M. Tumor markers in the diagnosis, monitoring and therapy of pancreatic cancer: state of the art Int J Biol Markers 10 1995 189 199
27. Posner M. Mayer R. The use of serologic tumor markers in gastrointestinal malignancies Hematol Oncol Clin North Am 8 1994 533 553
28. Ritts R. Del Villlano B. Go V. Initial clinical evaluation for an immunoradiometric assay for CA 19-9 using the NCI serum bank Int J Cancer 33 1984 339
29. Ritts R. Nagorney D. Jacobsen D. Comparison of preoperative serum CA 19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease Pancreas 9 1994 707 716
30. Safi F. Beger H. Bittner R. CA 19-9 and pancreatic adenocarcinoma Cancer 57 1986 779
31. Safi F. Schlosser W. Falkenreck S. CA 19-9 serum course and prognosis of pancreatic cancer Int J Pancreatol 20 1996 155 161
32. Safi F. Kolb G. Beger H. Clinical relevance of CA 19-9 in diagnosing and monitoring pancreatic cancer with special reference to the Lewis phenotype (abstract) Programs and Abstracts of the Annual Meeting of the American Association for Cancer Research 1995 A1326
33. Satake K. Chung Y-S Umeyama K. The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumor markers Cancer 68 1991 149 152
34. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen Am J Gastroenterol 85 1990 350 355
35. Steinberg W. Gelfand R. Anderson K. Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas Gastroenterology 90 1986 343 349
36. Tian F. Apert H. Myles J. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma Ann Surg 215 1992 350 355
37. Tolliver B. O’Brien B. Elevated tumor-associated antigen CA 19-9 in a patient with an enlarged pancreas: Does it always imply malignancy? South Med J 90 1997 89 90
38. van den Bosch R. van Eijck C. Mulder P. Serum CA 19-9 determination in the management of pancreatic cancer Hepatogastroenterology 43 1996 710 713
39. Willett C. Daly W. Warshaw A. CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer Am J Surg 172 1996 350 352
40. Yasue M. Sakamoto J. Teramukai S. Prognostic values of preoperative and postoperative CEA and CA 19-9 levels in pancreatic cancer Pancreas 9 1994 735 740